Alamar Biosciences, Inc. (ALMR) 2026 UBS Global Healthcare Conference November 10, 2026 5:00 PM EST
Company Participants
Justin McAnear – Chief Financial Officer
Conference Call Participants
Douglas Schenkel – UBS Investment Bank, Research Division
Presentation
Douglas Schenkel
UBS Investment Bank, Research Division
Good afternoon. My name is Doug Schenkel. And on behalf of UBS, it’s my pleasure to welcome Justin McAnear, Chief Financial Officer of Alamar to the 2026 Healthcare Conference. So Alamar is a relatively new issue, really exciting, relatively new entrant to the public company arena. It’s a fantastic platform that launched in early 2024. And since then, the company has seen rapid adoption across both the academic and biopharmaceutical end markets. The company reported another strong quarter last week with revenue up, I think it was 68%. So…
Justin McAnear
Chief Financial Officer
That’s right.
Douglas Schenkel
UBS Investment Bank, Research Division
Not too shabby. Consumables up 79%, gross margin getting to a record 61.5%. The company also announced a major collaboration with the U.K. Biobank and GSK. And on top of it, you raised your 2026 revenue outlook. So that was a good call. What I was thinking we could do is talk a bit about those developments as a starting point and then really turn to the more longer-term outlook for durable growth driven by improved installed base economics, content expansion and a more pronounced move into diagnostics. So that is the agenda.
Justin McAnear
Chief Financial Officer
That sounds like a great list.
Douglas Schenkel
UBS Investment Bank, Research Division
Yes, let’s see what we can do.
Justin McAnear
Chief Financial Officer
Yes. Happy to be here. And thank you very much for having us.
Question-and-Answer Session
Douglas Schenkel
UBS Investment Bank, Research Division
Awesome. So Justin, you and I have known each other for a little bit. What attracted you
